Staten Island, NY (PressExposure) February 21, 2013 -- Total gross proceeds raised are $6.9 million. DelMar Pharmaceuticals, Inc. (DMPI) ("DelMar") today announced the second closing in a private placement consisting of approximately 1.9 million units of its securities to qualified accredited investors, for gross proceeds of approximately $1.5 million. The total amount raised in the private placement is $6.9 million.
DelMar announced a first closing of $5.4 million on January 25, 2013.
Charles Vista LLC acted as the company's placement agent in the unit offering. Each unit consists of one share of common stock and one common stock purchase warrant.
Jeffrey Bacha, Chief Executive Officer of DelMar, commented "We are pleased to announce this second closing to raise additional funds and are very encouraged by the overall level of investor interest in our private placement. We continue to enhance our financial position to expand and accelerate our drug development activities with our lead drug candidate, VAL-083."
About DelMar Pharma
Del Mar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the United States as a potential treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. VAL-083 benefits from extensive clinical research sponsored by the US National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.
For further information, please visit http://www.delmarpharma.com; or contact Jeffrey A. Bacha, President & CEO (604) 629-5989 About Charles Vista, LLC
Charles Vista is a premier full service Broker Dealer and Investment Banking firm with an exceptional focus on client relationships. The Charles Vista team includes top entrepreneurs and remain committed to their goal of reshaping the financial industry through successful client relationship and partnerships. For the last decade, Charles Vista has provided innovative development in each financial deal. The Charles Vista approach uses a combination of traditional investment practices mixed with alternative investments such as Late Stage Venture Capital. Charles Vista clients are given the opportunity to grow their capital with well-crafted deals and partnerships.